AKRSX | GFFFX | AKRSX / GFFFX | |
Total Expense Ratio | 0.98 | 0.40 | 245% |
Annual Report Gross Expense Ratio | 0.98 | 0.40 | 245% |
Fund Existence | 10 years | 17 years | - |
Gain YTD | 9.062 | 14.507 | 62% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 300000000 | 250 | 120,000,000% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 12.2B | 329B | 4% |
Annual Yield % from dividends | 0.00 | 0.52 | - |
Returns for 1 year | 10.01 | 17.39 | 58% |
Returns for 3 years | 25.92 | 43.38 | 60% |
Returns for 5 years | 41.17 | 45.60 | 90% |
Returns for 10 years | N/A | 88.51 | - |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
THNR | 22.55 | 0.05 | +0.21% |
Amplify Weight Loss Drug & Treatment ETF | |||
BALI | 31.02 | 0.04 | +0.13% |
iShares Advantage Large Cap Income ETF | |||
XTOC | 32.17 | -0.03 | -0.08% |
Innovator US Equity Acclrtd Pls ETF™ Oct | |||
DCOR | 69.88 | -0.12 | -0.17% |
Dimensional US Core Equity 1 ETF | |||
FCVT | 39.99 | -0.15 | -0.38% |
First Trust SSI Strat Convert Secs ETF |